Minireview: Ribonucleic Acid Interference for the Identification of New Targets for the Treatment of Metabolic Diseases

Over the past years, RNA interference (RNAi) has exploded as a new approach to manipulate gene expression in mammalian systems. More recently, RNAi has acquired interest as a tool to identify new targets for therapeutic intervention. This review focuses on the current understanding of RNAi biology,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Endocrinology (Philadelphia) 2006-06, Vol.147 (6), p.2650-2656
1. Verfasser:	Rondinone, Cristina M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoviridae - genetics Agouti-Related Protein Animals Apolipoproteins B - genetics Biological and medical sciences Diabetes mellitus Diabetes Mellitus - therapy Drug development Early Growth Response Protein 1 - genetics Fundamental and applied biological sciences. Psychology Gene expression Humans In vivo methods and tests Insulin - physiology Insulin Receptor Substrate Proteins Intercellular Signaling Peptides and Proteins Metabolic disorders Obesity - therapy Pathogenesis Phosphoproteins - genetics Proteins - genetics RNA Interference RNA-mediated interference Signal Transduction Target acquisition Target recognition Transcription Factors - genetics Vertebrates: endocrinology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Over the past years, RNA interference (RNAi) has exploded as a new approach to manipulate gene expression in mammalian systems. More recently, RNAi has acquired interest as a tool to identify new targets for therapeutic intervention. This review focuses on the current understanding of RNAi biology, how RNAi has been used to study the role of different genes in the pathogenesis of diabetes and obesity, and the use of RNAi screens for the identification of new targets for metabolic diseases. Also reviewed are the in vivo proof of principle experiments that provide the validation of these new targets for the development of RNAi-based therapeutics for diabetes.
ISSN:	0013-7227 1945-7170
DOI:	10.1210/en.2006-0147